{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T02:11:52Z","timestamp":1723169512737},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2016,12,29]],"date-time":"2016-12-29T00:00:00Z","timestamp":1482969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,12,29]],"date-time":"2016-12-29T00:00:00Z","timestamp":1482969600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hum Hypertens"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1038\/jhh.2016.95","type":"journal-article","created":{"date-parts":[[2016,12,29]],"date-time":"2016-12-29T10:22:38Z","timestamp":1483006958000},"page":"450-456","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Preventive effect of renin-angiotensin system inhibitors on new-onset atrial fibrillation in hypertensive patients: a propensity score matching analysis"],"prefix":"10.1038","volume":"31","author":[{"given":"T","family":"Horio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Akiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Iwashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Yoshihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Tokudome","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Okutsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I","family":"Komatsubara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Okimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Kamakura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Kawano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,12,29]]},"reference":[{"key":"BFjhh201695_CR1","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1161\/01.CIR.98.24.2765","volume":"98","author":"PE McEwan","year":"1998","unstructured":"McEwan PE, Gray GA, Sherry L, Webb DJ, Kenyon CJ . Differential effects of angiotensin II on cardiac cell proliferation and intramyocardial perivascular fibrosisin vivo. Circulation 1998; 98: 2765\u20132773.","journal-title":"Circulation"},{"key":"BFjhh201695_CR2","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.ejheart.2008.09.014","volume":"10","author":"D von Lewinski","year":"2008","unstructured":"von Lewinski D, Kocksk\u00e4mper J, R\u00fcbertus SU, Zhu D, Schmitto JD, Sch\u00f6ndube FA et al. Direct pro-arrhythmogenic effects of angiotensin II can be suppressed by AT1 receptor blockade in human atrial myocardium. Eur J Heart Fail 2008; 10: 1172\u20131176.","journal-title":"Eur J Heart Fail"},{"key":"BFjhh201695_CR3","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.ahj.2004.09.033","volume":"149","author":"AP Maggioni","year":"2005","unstructured":"Maggioni AP, Latini R, Carson PE, Singh SN, Barlera S, Glazer R et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 2005; 149: 548\u2013557.","journal-title":"Am Heart J"},{"key":"BFjhh201695_CR4","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.jacc.2004.10.068","volume":"45","author":"K Wachtell","year":"2005","unstructured":"Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahl\u00f6f B et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005; 45: 712\u2013719.","journal-title":"J Am Coll Cardiol"},{"key":"BFjhh201695_CR5","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1097\/HJH.0b013e3282f35c67","volume":"26","author":"RE Schmieder","year":"2008","unstructured":"Schmieder RE, Kjeldsen SE, Julius S, McInnes GT, Zanchetti A, Hua TA . Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial. J Hypertens 2008; 26: 403\u2013411.","journal-title":"J Hypertens"},{"key":"BFjhh201695_CR6","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1016\/j.jacc.2004.11.070","volume":"45","author":"JS Healey","year":"2005","unstructured":"Healey JS, Baranchuk A, Crystal E, Morillo CA, Garfinkle M, Yusuf S et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 2005; 45: 1832\u20131839.","journal-title":"J Am Coll Cardiol"},{"key":"BFjhh201695_CR7","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1016\/j.jacc.2010.01.043","volume":"55","author":"MP Schneider","year":"2010","unstructured":"Schneider MP, Hua TA, B\u00f6hm M, Wachtell K, Kjeldsen SE, Schmieder RE . Prevention of atrial fibrillation by Renin-Angiotensin system inhibition a meta-analysis. J Am Coll Cardiol 2010; 55: 2299\u20132307.","journal-title":"J Am Coll Cardiol"},{"key":"BFjhh201695_CR8","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1111\/j.1365-2362.2010.02460.x","volume":"41","author":"G Huang","year":"2011","unstructured":"Huang G, Xu JB, Liu JX, He Y, Nie XL, Li Q et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers decrease the incidence of atrial fibrillation: a meta-analysis. Eur J Clin Invest 2011; 41: 719\u2013733.","journal-title":"Eur J Clin Invest"},{"key":"BFjhh201695_CR9","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1056\/NEJMoa0805710","volume":"360","author":"M Disertori","year":"2009","unstructured":"Disertori M, Latini R, Barlera S, Franzosi MG, Staszewsky L, Maggioni AP et al. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med 2009; 360: 1606\u20131617.","journal-title":"N Engl J Med"},{"key":"BFjhh201695_CR10","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1093\/europace\/euq439","volume":"13","author":"T Yamashita","year":"2011","unstructured":"Yamashita T, Inoue H, Okumura K, Kodama I, Aizawa Y, Atarashi H et al. Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study). Europace 2011; 13: 473\u2013479.","journal-title":"Europace"},{"key":"BFjhh201695_CR11","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1161\/CIRCEP.111.965178","volume":"5","author":"A Goette","year":"2012","unstructured":"Goette A, Sch\u00f6n N, Kirchhof P, Breithardt G, Fetsch T, H\u00e4usler KG et al. Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial. Circ Arrhythm Electrophysiol 2012; 5: 43\u201351.","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"BFjhh201695_CR12","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1097\/HJH.0b013e32833a7dfe","volume":"28","author":"T Horio","year":"2010","unstructured":"Horio T, Iwashima Y, Kamide K, Tokudome T, Yoshihara F, Nakamura S et al. Chronic kidney disease as an independent risk factor for new-onset atrial fibrillation in hypertensive patients. J Hypertens 2010; 28: 1738\u20131744.","journal-title":"J Hypertens"},{"key":"BFjhh201695_CR13","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1161\/01.HYP.0000200033.14574.14","volume":"47","author":"Y Iwashima","year":"2006","unstructured":"Iwashima Y, Horio T, Kamide K, Rakugi H, Ogihara T, Kawano Y . Uric acid, left ventricular mass index, and risk of cardiovascular disease in essential hypertension. Hypertension 2006; 47: 195\u2013202.","journal-title":"Hypertension"},{"key":"BFjhh201695_CR14","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1161\/01.CIR.55.4.613","volume":"55","author":"RB Devereux","year":"1977","unstructured":"Devereux RB, Reichek N . Echocardiographic determination of left ventricular mass in man: anatomic validation of the method. Circulation 1977; 55: 613\u2013618.","journal-title":"Circulation"},{"key":"BFjhh201695_CR15","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1097\/HJH.0b013e3282f3eb3d","volume":"26","author":"Y Iwashima","year":"2008","unstructured":"Iwashima Y, Horio T, Kamide K, Rakugi H, Ogihara T, Kawano Y . Pulmonary venous flow and risk of cardiovascular disease in essential hypertension. J Hypertens 2008; 26: 798\u2013805.","journal-title":"J Hypertens"},{"key":"BFjhh201695_CR16","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53: 982\u2013992.","journal-title":"Am J Kidney Dis"},{"key":"BFjhh201695_CR17","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1002\/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B","volume":"17","author":"RB D\u2019Agostino Jr","year":"1998","unstructured":"D\u2019Agostino RB Jr . Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998; 17: 2265\u20132281.","journal-title":"Stat Med"},{"key":"BFjhh201695_CR18","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1177\/0193841X05275596","volume":"29","author":"JK Luellen","year":"2005","unstructured":"Luellen JK, Shadish WR, Clark MH . Propensity scores: an introduction and experimental test. Eval Rev 2005; 29: 530\u2013558.","journal-title":"Eval Rev"},{"key":"BFjhh201695_CR19","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S0140-6736(98)05012-0","volume":"353","author":"L Hansson","year":"1999","unstructured":"Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611\u2013616.","journal-title":"Lancet"},{"key":"BFjhh201695_CR20","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1016\/S0140-6736(99)10327-1","volume":"354","author":"L Hansson","year":"1999","unstructured":"Hansson L, Lindholm LH, Ekbom T, Dahl\u00f6f B, Lanke J, Scherst\u00e9n B et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354: 1751\u20131756.","journal-title":"Lancet"},{"key":"BFjhh201695_CR21","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.ahj.2007.04.062","volume":"154","author":"O Salehian","year":"2007","unstructured":"Salehian O, Healey J, Stambler B, Alnemer K, Almerri K, Grover J et al. Impact of ramipril on the incidence of atrial fibrillation: results of the Heart Outcomes Prevention Evaluation study. Am Heart J 2007; 154: 448\u2013453.","journal-title":"Am Heart J"},{"key":"BFjhh201695_CR22","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/S0140-6736(08)61193-9","volume":"372","author":"S Yusuf","year":"2008","unstructured":"Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008; 372: 1174\u20131183.","journal-title":"Lancet"},{"key":"BFjhh201695_CR23","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/ajh.2009.33","volume":"22","author":"SR Heckbert","year":"2009","unstructured":"Heckbert SR, Wiggins KL, Glazer NL, Dublin S, Psaty BM, Smith NL et al. Antihypertensive treatment with ACE inhibitors or beta-blockers and risk of incident atrial fibrillation in a general hypertensive population. Am J Hypertens 2009; 22: 538\u2013544.","journal-title":"Am J Hypertens"},{"key":"BFjhh201695_CR24","doi-asserted-by":"publisher","first-page":"78","DOI":"10.7326\/0003-4819-152-2-201001190-00005","volume":"152","author":"BA Schaer","year":"2010","unstructured":"Schaer BA, Schneider C, Jick SS, Conen D, Osswald S, Meier CR . Risk for incident atrial fibrillation in patients who receive antihypertensive drugs: a nested case-control study. Ann Intern Med 2010; 152: 78\u201384.","journal-title":"Ann Intern Med"},{"key":"BFjhh201695_CR25","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jacc.2004.03.056","volume":"44","author":"PL L\u2019Allier","year":"2004","unstructured":"L\u2019Allier PL, Ducharme A, Keller PF, Yu H, Guertin MC, Tardif JC . Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation. J Am Coll Cardiol 2004; 44: 159\u2013164.","journal-title":"J Am Coll Cardiol"},{"key":"BFjhh201695_CR26","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1038\/hr.2014.104","volume":"37","author":"GP Jong","year":"2014","unstructured":"Jong GP, Chen HY, Li SY, Liou YS . Long-term effect of antihypertensive drugs on the risk of new-onset atrial fibrillation: a longitudinal cohort study. Hypertens Res 2014; 37: 950\u2013953.","journal-title":"Hypertens Res"},{"key":"BFjhh201695_CR27","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1093\/eurheartj\/eht507","volume":"35","author":"SC Marott","year":"2014","unstructured":"Marott SC, Nielsen SF, Benn M, Nordestgaard BG . Antihypertensive treatment and risk of atrial fibrillation: a nationwide study. Eur Heart J 2014; 35: 1205\u20131214.","journal-title":"Eur Heart J"},{"key":"BFjhh201695_CR28","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1161\/01.CIR.0000022665.18619.83","volume":"106","author":"AH Madrid","year":"2002","unstructured":"Madrid AH, Bueno MG, Rebollo JM, Mar\u00edn I, Pe\u00f1a G, Bernal E et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 2002; 106: 331\u2013336.","journal-title":"Circulation"},{"key":"BFjhh201695_CR29","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1016\/j.ehj.2003.08.014","volume":"24","author":"KC Ueng","year":"2003","unstructured":"Ueng KC, Tsai TP, Yu WC, Tsai CF, Lin MC, Chan KC et al. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. Eur Heart J 2003; 24: 2090\u20132098.","journal-title":"Eur Heart J"},{"key":"BFjhh201695_CR30","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1093\/eurheartj\/ehl135","volume":"27","author":"Y Yin","year":"2006","unstructured":"Yin Y, Dalal D, Liu Z, Wu J, Liu D, Lan X et al. Prospective randomized study comparing amiodarone vs. amiodarone plus losartan vs. amiodarone plus perindopril for the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation. Eur Heart J 2006; 27: 1841\u20131846.","journal-title":"Eur Heart J"},{"key":"BFjhh201695_CR31","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1161\/HYPERTENSIONAHA.111.202309","volume":"61","author":"H Du","year":"2013","unstructured":"Du H, Fan J, Ling Z, Woo K, Su L, Chen S et al. Effect of nifedipine versus telmisartan on prevention of atrial fibrillation recurrence in hypertensive patients. Hypertension 2013; 61: 786\u2013792.","journal-title":"Hypertension"},{"key":"BFjhh201695_CR32","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1161\/01.HYP.0000052830.02773.E4","volume":"41","author":"P Verdecchia","year":"2003","unstructured":"Verdecchia P, Reboldi G, Gattobigio R, Bentivoglio M, Borgioni C, Angeli F et al. Atrial fibrillation in hypertension: predictors and outcome. Hypertension 2003; 41: 218\u2013223.","journal-title":"Hypertension"}],"container-title":["Journal of Human Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/jhh201695.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/jhh201695","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/jhh.2016.95","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/jhh201695.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T16:43:49Z","timestamp":1647535429000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/jhh201695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,29]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["BFjhh201695"],"URL":"https:\/\/doi.org\/10.1038\/jhh.2016.95","relation":{},"ISSN":["0950-9240","1476-5527"],"issn-type":[{"value":"0950-9240","type":"print"},{"value":"1476-5527","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,29]]},"assertion":[{"value":"30 July 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}